Listed

Ascentage Pharma Group International

AAPGNasdaqCIK 2023311HealthcareFiscal year ends Dec 31

Share

Share this page

Story card, 1080 × 1920

Standardized line items from XBRL company facts, the last twelve quarters. Negative values are in parentheses. A figure marked d is derived from year-to-date figures.

Balance sheet

Cash and equivalents$122.4m, FY2024
Shareholders' equity$36.2m, FY2024
Line itemUnitperiod not labelled2023-12-31FY20242024-12-31
Cash and equivalents$m142Cash and equivalents, period not labelled, at 2023-12-31$142.2m. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure122Cash and equivalents, FY2024, at 2024-12-31$122.4m. XBRL concept ifrs-full:CashAndCashEquivalents. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure
Current assets$mnot reported202Current assets, FY2024, at 2024-12-31$202.0m. XBRL concept ifrs-full:CurrentAssets. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure
Current liabilities$mnot reported160Current liabilities, FY2024, at 2024-12-31$159.8m. XBRL concept ifrs-full:CurrentLiabilities. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure
Total liabilities$mnot reported321Total liabilities, FY2024, at 2024-12-31$321.1m. XBRL concept ifrs-full:Liabilities. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure
Shareholders' equity$mnot reported36.2Shareholders' equity, FY2024, at 2024-12-31$36.2m. XBRL concept ifrs-full:EquityAttributableToOwnersOfParent. 20-F filed 2025-04-16, accession 0001213900-25-032599.Report this figure

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:50 ET. Listed shows no prices and gives no investment advice.